202 related articles for article (PubMed ID: 1586981)
1. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW
Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981
[TBL] [Abstract][Full Text] [Related]
2. Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane).
Chakrabarti KB; Hopewell JW; Wilding D; Plowman PN
Eur J Cancer; 2001 Jul; 37(11):1435-42. PubMed ID: 11435077
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
Herman EH; el-Hage A; Ferrans VJ
Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293
[TBL] [Abstract][Full Text] [Related]
4. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
Herman EH; Ferrans VJ; Bhat HB; Witiak DT
Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
Zhang J; Herman EH; Ferrans VJ
Am J Pathol; 1993 Jun; 142(6):1916-26. PubMed ID: 8506959
[TBL] [Abstract][Full Text] [Related]
6. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
Villani F; Galimberti M; Monti E; Cova D; Lanza E; Rozza-Dionigi A; Favalli L; Poggi P
Toxicol Appl Pharmacol; 1990 Feb; 102(2):292-9. PubMed ID: 2105541
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
8. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192
[TBL] [Abstract][Full Text] [Related]
9. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
Shipp NG; Dorr RT; Alberts DS; Dawson BV; Hendrix M
Cancer Res; 1993 Feb; 53(3):550-6. PubMed ID: 8425187
[TBL] [Abstract][Full Text] [Related]
10. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats.
Dardir M; Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1989; 23(5):269-75. PubMed ID: 2495862
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
[TBL] [Abstract][Full Text] [Related]
12. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors.
van Acker SA; Kramer K; Voest EE; Grimbergen JA; Zhang J; van der Vijgh WJ; Bast A
Cancer Chemother Pharmacol; 1996; 38(1):95-101. PubMed ID: 8603459
[TBL] [Abstract][Full Text] [Related]
14. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Zhang J; Herman EH; Ferrans VJ
Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
[TBL] [Abstract][Full Text] [Related]
15. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Herman EH; Zhang J; Ferrans VJ
Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
[TBL] [Abstract][Full Text] [Related]
18. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
Herman EH; Ferrans VJ
Cancer Res; 1981 Sep; 41(9 Pt 1):3436-40. PubMed ID: 6790165
[TBL] [Abstract][Full Text] [Related]
19. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.
Yeung TK; Hopewell JW; Simmonds RH; Seymour LW; Duncan R; Bellini O; Grandi M; Spreafico F; Strohalm J; Ulbrich K
Cancer Chemother Pharmacol; 1991; 29(2):105-11. PubMed ID: 1760851
[TBL] [Abstract][Full Text] [Related]
20. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
Herman EH; Ferrans VJ
Lab Invest; 1983 Jul; 49(1):69-77. PubMed ID: 6408310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
